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months after initiation of therapy. Secondary endpoints 
were central retinal thickness and safety of the therapy ap-
plied.  Results: In group 1, an increase in BCVA of 2.5 ( 8 1.6) 
letters in the CRVO and of 13.0 ( 8 3.2) letters in BRVO patients 
was seen after 6 months, in group 2 of 5.9 ( 8 0.4) letters 
(CRVO) and 3.8 ( 8 2.4) letters (BRVO), which was not statisti-
cally significant. When comparing the two treatment groups 
with respect to the type of vein occlusion, there was a sig-
nificant advantage for BRVO patients for the dexametha-
sone implant monotherapy (BRVO patients in group 1, p = 
0.005). Central retinal thickness showed a significant reduc-
tion after 6 months only in patients of group 1, both for CRVO 
(p = 0.01) and BRVO (p = 0.003). First recurrence after the first 
dexamethasone implant injection occurred after 3.8 months 
(mean) in CRVO and 3.5 months in BRVO patients (group 1), 
versus 3.2 and 3.7 months, respectively, in group 2. In group 
1, 63.6% with CRVO and 50% with BRVO showed an increased 
intraocular pressure after treatment; in group 2, 57.1% with 
CRVO and 50.0% with BRVO, respectively.  Conclusion: In 
CRVO, there was no difference between the two treatment 
strategies investigated. However, in BRVO, dexamethasone 
implant monotherapy was associated with better functional 
outcome. 
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 Abstract 
 Purpose: To compare the efficacy and safety of three intra-
vitreal bevacizumab upload injections followed by a dexa-
methasone implant versus dexamethasone implant mono-
therapy in eyes with macular edema due to retinal vein
occlusion.  Methods: Sixty-four eyes of 64 patients were
included in this prospective, consecutive, nonrandomized 
case series: group 1 consisted of 38 patients (22 with central 
retinal vein occlusion, CRVO, 16 with branch retinal vein oc-
clusion, BRVO) treated using a dexamethasone implant 
(Ozurdex) alone; group 2 consisted of 26 patients (14 CRVO, 
12 BRVO) treated with three consecutive intravitreal bevaci-
zumab injections at monthly intervals followed by a dexa-
methasone implant. In case of recurrence, both cohorts re-
ceived further dexamethasone implants. Preoperatively and 
monthly best corrected visual acuity (BCVA, ETDRS), central 
retinal thickness (Spectralis-OCT), intraocular pressure, and 
wide-angle fundus photodocumentation (Optomap) were 
performed. The primary clinical endpoint was BCVA at 6 
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 Introduction 
 Retinal vein occlusion (RVO) is a major cause of vi-
sual loss in industrialized countries. Branch retinal vein 
occlusion (BRVO) is more common than central retinal 
vein occlusion (CRVO). In both types, the underlying 
cause of functional deterioration is macular edema. In 
case of extensive ischemia, neovascularization may occur 
at the posterior and anterior segment of the eye and lead 
to severe complications including blindness especially in 
eyes with CRVO  [1] . The pathogenesis of macular edema 
in RVO is not completely understood. However, some 
causative factors have been identified such as the role of 
hydrostatic effects from increased venous pressure, the 
presence of inflammatory cytokines (e.g., prostaglandins 
and interleukin-6), and the dysregulation of endothelial 
tight junction proteins  [2] , or increased vascular endothe-
lial growth factor (VEGF) expression  [3] . Risk factors for 
RVO include arterial hypertension, hypercholesterol-
emia, diabetes mellitus, and glaucoma  [4] .
 Recently, two pharmacological treatment regimens 
have been introduced for the treatment of macular edema 
associated with RVO including intravitreal injection of 
VEGF inhibitors such as bevacizumab and corticoste-
roids such as dexamethasone. While bevacizumab is still 
off label, a sustained-release dexamethasone implant has 
been approved  [5–7] .
 The aim of this study was to compare the efficacy and 
safety of an anti-VEGF upload using bevacizumab fol-
lowed by a dexamethasone implant versus dexametha-
sone implant monotherapy as a first-line treatment regi-
men in patients with CRVO and BRVO.
 Materials and Methods 
 In this prospective, consecutive, nonrandomized case series 
64 eyes of 64 patients with RVO, 39 males and 25 females with a 
mean age of 68.0 years, were included. Thirty-six patients pre-
sented with (nonischemic) CRVO, 28 with BRVO. Only patients 
with a maximum duration of symptoms of 4 months were includ-
ed. None of the patients had a known history of glaucoma or cor-
ticosteroid response in the past. Patients were recruited between 
September 2010 and January 2011.
 Patients were recruited in a consecutive manner, starting with 
the combined group. Group 1, including 38 patients (22 with 
CRVO and 16 with BRVO), was treated with a dexamethasone 
implant from the beginning. Group 2, including 26 patients (14 
CRVO, 12 BRVO), was treated with three consecutive injections 
of bevacizumab at monthly intervals, followed by a dexametha-
sone implant at week 16. Then, both groups received dexametha-
sone implants once macular edema recurred ( fig. 1 ). Our criteria 
for retreatment included a loss of best corrected visual acuity 
(BCVA) of more than 5 letters (ETDRS) and/or an increase in 
retinal thickness on optical coherence tomography (OCT) of 
more than 100   m. We measured BCVA (ETDRS chart), central 
retinal thickness (Spectralis-OCT, Heidelberg Engineering, Ger-
many), as well as intraocular pressure and we took wide-angle 
retinal images (Optomap OPTOS, Bruchsal, Germany) at initia-
tion of treatment and then at monthly intervals. Fluoresceine an-
giography was performed initially and after 3 months.
 The primary clinical endpoint was a gain in BCVA 6 months 
after the first intravitreal treatment. Secondary endpoints were 
central retinal thickness and the safety of the procedure.
 Statistical Analysis 
 Data were collected using Microsoft Excel spreadsheets (Mi-
crosoft Excel 2003) and statistical analysis was performed using 
SPSS (IBM SPSS Version 19). Student’s t test and Wilcoxon rank 
test were used to compare both data cohorts and to calculate sig-
nificance. A p value below 0.05 was considered significant. All 
tests were two-sided.
 Results 
 Efficacy 
 At baseline, mean BCVA was 22.4 letters (SD  8 12.3 
letters) in CRVO and 26.3 letters (range 9.9 letters) in 
BRVO patients in group 1, and 15.5  8 10.6 letters versus 
28.5  8 10.3 letters in group 2, respectively. Mean macu-
lar thickness was found to be 604.4   m (range  8 230.5 
  m) in CRVO and 500.5   m (range  8 106   m) in BRVO 
patients in group 1 and 601.1   m (range  8 252.5   m) ver-
sus 469.8   m (range  8 151.7   m) in group 2. 
 In group 1, at 6 months after initiation of therapy an 
increase in BCVA ( 8 1 standard deviation) of 2.5 ( 8 1.6) 
letters was observed in CRVO ( fig. 2 a,  3 a, b) and of 13.0 
( 8 3.2) letters in BRVO patients ( fig. 2 b). In group 2, CRVO 
patients showed an increase in BCVA ( 8 1 standard devia-
tion) of 5.9 ( 8 0.4) letters ( fig. 2 a) compared to 3.8 ( 8 2.4) 
letters in BRVO patients ( fig. 2 b). When comparing the two 
treatment groups with respect to the subtype of vein occlu-
sion, there was no significant difference after 6 months, 
except for BRVO patients treated with the dexamethasone 
implant alone (BRVO patients in group 1, p = 0.005,  fig. 2 b). 
However, comparing area under the curve analyses, high-
est values could only be obtained in CRVO patients using 
the combined therapy regimen (65.4 vs. 56.8, p  ! 0.05). In 
BRVO no marked differences could be found (34.8 vs. 33.4, 
p = 0.40) in this follow-up period. The maximum treat-
ment effect in terms of visual gain was seen after the first 
month, after the dexamethasone implantation as well as 
after the first injection of bevacizumab. There was a non-
significant difference in gain of BCVA comparing the two 
treatment modalities in CRVO patients ( fig. 2 a).
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 OCT measurements showed a significant reduction of 
central retinal thickness after 6 months in group 1, both 
for CRVO patients (p = 0.01,  fig. 4 a,  5 ) and BRVO patients 
(p = 0.003,  fig. 4 b). No effect was seen at 6 months for 
CRVO and BRVO patients in group 2.
 In group 1, 16/22 (72.7%) CRVO patients experienced 
a recurrence after a mean period of 3.8 ( 8 1.25) months 
versus 6/16 (37.5%) BRVO patients after a mean period of 
3.5 ( 8 0.63) months after the first dexamethasone im-
plant. In group 2, recurrences after the first dexametha-
sone implant (following three consecutive injections of 
bevacizumab) occurred after a mean follow-up of 3.2 
( 8 0.5) months in 9/14 (64.3%) CRVO patients, and after 
3.7 ( 8 0.75) months in 7/12 (58.3%) BRVO patients ( ta-
ble 1 ).
 During the entire period of 6 months, the total num-
ber of retreatments using dexamethasone implant was 
25/38 (65.8%) in group 1 versus 24/26 in group 2 (92.3%). 
 Safety 
 Before initiation of treatment intraocular pressure was 
within the normal range in all patients. A relevant in-
crease in intraocular pressure was defined as an increase 
of  1 5 mm Hg compared to baseline. During the 6-month 
follow-up, 22/38 (57.9%) patients in group 1 experienced 
an increase in intraocular pressure (14/22 CRVO patients, 
Group 1
Ozurdex Ozurdex if recurrence
Avastin
1st month 2nd month 3rd month 4th month 5th month 6th month
Avastin Avastin Ozurdex Ozurdex if recurrence
Group 2
 Fig. 1. Treatment strategy (timeline): primary dexamethasone implant therapy (group 1) versus bevacizumab 
pretreatment and subsequent dexamethasone implant therapy (group 2). During the study period, recurrence 
was treated in both groups at a loss of visual acuity of  1 5 letters (ETDRS) and/or increase of central retinal 
thickness in OCT measurements of more than 100   m. 
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 Fig. 2.  a ,  b Visual acuity compared to baseline: 6-month follow-up in both treatment groups after initial ther-
apy in patients with CRVO ( a ) and BRVO ( b ). 
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63.6%; 8/16 BRVO patients, 50%). In group 2, an increase 
in intraocular pressure was seen in 14/26 (53.8%) patients, 
8/14 (57.1%) CRVO, and 6/12 (50.0%) BRVO patients ( ta-
ble 1 ). Intraocular pressure exceeding the normal range 
was controlled by topical drugs. One eye in group 1 re-
quired cyclophotocoagulation after the second dexa-
methasone implant.
 In 1 CRVO patient of group 1 localized retinal detach-
ment occurred 3 weeks after implantation, which was 
successfully reattached with a scleral buckle. No other 
adverse events such as intravitreal hemorrhage or en-
dophthalmitis were noted. No accelerated cataract for-
mation was noted. Sixteen patients were pseudophakic at 
study entry.
 Discussion 
 Until recently, our treatment strategy for patients with 
BRVO and CRVO was mainly based on the results of 
BRVO and CRVO trials  [8, 9] , suggesting deferred focal 
laser for macular edema in BRVO patients with BCVA 
below 20/40. Peripheral laser was advocated in cases with 
severe ischemia in BRVO and CRVO in order to treat or 
prevent neovascularization at the posterior or anterior 
segment of the eye and to prevent neovascular glaucoma, 
especially in CRVO. We knew that laser photocoagula-
tion of the macular region had no benefit for macular 
function in eyes with CRVO at all  [8] .
 In contrast, since the advent of pharmacological treat-
ment options including the intravitreal application of 
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 Fig. 3.  a ,  b Change in retinal thickness using spectral domain OCT: 6-month follow-up in both treatment groups
after initial therapy in patients with CRVO (a) and BRVO (b). 
Table 1. O verview of the 6-month follow-up of all groups after primary intravitreal therapy
BCVA (ETDRS) Recurrence
(n/months)
O CT (m) IOP (n/%)
increase > 
 5 mm Hg
Adverse 
eventsPreOP 6 months PreOP 6 months
Monotherapy Ozurdex – CRVO (n = 22) 22.4 24.9 16/3.8 604.4 438.1 14/63.6 1
Monotherapy Ozurdex – BRVO (n = 16) 26.3 39.2  6/3.5 500.5 324.8 08/50.0 0
Combined therapy Ozurdex/Avastin – CRVO (n = 14) 15.5 21.4  9/3.2 543.1 436.7 08/57.1 0
Combined therapy Ozurdex/Avastin – BRVO (n = 12) 28.6 32.4  7/3.7 479.6 422.3 06/50.0 0
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corticosteroids  [6, 7] and anti-VEGF drugs  [5, 10] , pa-
tients with RVO, both CRVO and BRVO, have a better 
chance of visual recovery.
 Both pharmacological approaches address important 
issues in the pathogenesis of retinal vascular occlusion, 
such as the expression of VEGF in the vitreous  [11] and 
inflammatory processes  [12–16] . Corticosteroids not 
only have an anti-inflammatory effect (e.g. inhibition of 
fibrin deposition, leukocyte movement, suppression of 
homing and migration of inflammatory cells), but also 
interfere with the synthesis of VEGF and other cytokines 
 [2, 17] .
 Dexamethasone is a potent, water-soluble corticoste-
roid which can be delivered into the vitreous cavity either 
by injection of a dexamethasone solution with a very 
short half-life  [18] , or by the implantation of an approved 
dexamethasone intravitreal implant using a customized 
applicator system (Ozurdex, Allergan, Inc., Irvine, Calif., 
USA)  [6] . Dexamethasone is then released over a pro-
longed period of up to 6 months until complete resolution 
of the matrix, and has a beneficial effect on visual acuity 
and retinal thickness in patients with macular edema as-
sociated with BRVO and CRVO  [6] .
 Anti-VEGF drugs, such as ranibizumab, also have a 
beneficial effect on visual function and reduce central 
macular thickness in BRVO and CRVO eyes  [5, 10, 19, 20] . 
However, with respect to the shorter half-life of ranibi-
zumab  [21] numerous injections are required to achieve 
and maintain this therapeutic effect. Of note, ranibizum-
ab was not approved for the treatment of RVO at the be-
 Fig. 4. Spectralis-OCT images of the macular area of a CRVO case: 3-month course of primary dexamethasone 
implant therapy. 
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ginning of this study. Therefore, bevacizumab was used 
for treatment in an off-label setting after IRB approval. 
 The aim of the present study was to compare the effi-
cacy of these two treatment regimens and to assess wheth-
er the initial treatment with an anti-VEGF drug has an 
impact on the interval until the recurrence of macular 
edema.
 We observed that pretreatment with 3 doses of bevaci-
zumab in combination followed by a single dexametha-
sone implant was not effective in prolonging this interval 
compared to monotherapy using the dexamethasone im-
plant in the first instance. Recurrences occurred between 
3.2 and 3.8 months and were in line with the known phar-
macokinetics of the dexamethasone implant and the re-
sults of the GENEVA trial, which revealed a decrease in 
the treatment effect at about 3–4 months after implanta-
tion  [6] . Interestingly, the number of recurrences (and sub-
sequent retreatments) in patients receiving monotherapy 
with the dexamethasone implant was lower in BRVO com-
pared to CRVO patients, which may well be explained by 
the more favorable natural history of macular edema as-
sociated with BRVO. Therefore, considering the potential 
adverse effect of a corticosteroidal implant, BRVO patients 
seem better candidates for this treatment as a first-line op-
tion compared to CRVO patients, as the latter require 
more retreatments as described in other trials, too  [10, 19] .
 Furthermore, monotherapy using the dexamethasone 
implant was especially beneficial in BRVO patients and 
led to a significant gain of 13.0 letters in contrast to CRVO 
patients with a gain of only 2.5 letters. However, area un-
der the curve analyses showed no marked differences in 
BRVO patients. In contrast, the combination therapy led 
to better functional improvement in CRVO patients (5.9 
letters) when compared to monotherapy. 
 We are aware that the study population was limited 
and the baseline data range for all subjects was at a high-
er level concerning BCVA and OCT measurements com-
pared to the GENEVA trial. Therefore, the improvement 
of visual acuity (gain in letters) after retreatment with the 
dexamethasone implant was not as high as that observed 
in the GENEVA trial.
 As expected for a corticosteroid, we observed elevation 
of intraocular pressure, which was controlled by anti-
glaucomatous topical drops in all cases except 1 case, that 
underwent cyclophotocoagulation after the second dexa-
methasone implant. In patients receiving monotherapy 
intraocular pressure was found to be elevated during fol-
low-up in 63.6% of CRVO eyes, and 50% of BRVO eyes, 
compared to 57.1% in CRVO, and 50.0% in BRVO eyes 
pretreated with bevacizumab. This raises the question 
whether the subsequent implantation of a dexametha-
sone implant after a period of 3–4 months increases the 
risk of intraocular pressure elevation, when the partially 
degraded first implant still releases the drug into the vit-
reous cavity. In contrast, in the GENEVA trial no such 
additional effect could occur, because reinjection was not 
permitted within 6 months. The same considerations 
may theoretically apply for the formation of cataract in 
a b
 Fig. 5. a,  b Fundus documentation (Optomap) of a patient with CRVO before (a) and 3 months after (b) pri-
mary dexamethasone implant therapy. 
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phakic eyes. Therefore, the combination of a dexametha-
sone implant with an anti-VEGF drug or a switch from 
dexamethasone monotherapy to an anti-VEGF strategy 
may be an option in selected cases, e.g. especially in 
CRVO patients, where the natural history is quite poor 
compared to patients with BRVO and more treatments 
seem to be required to maintain function  [10, 19] .
 The limitation of the present study is the relatively 
short period of follow-up. However, our aim was to inves-
tigate the response to two different treatment options in 
patients with RVO. We are aware that the results seen for 
bevacizumab may not necessarily be transferred to the 
results one may obtain using ranibizumab in a similar 
setting. Of note, ranibizumab was not approved for the 
treatment of RVO at the start of our trial. A longer period 
of review will be needed to document the sustainability 
of the treatment benefit using dexamethasone monother-
apy especially in BRVO patients. In addition, especially 
the safety issues such as secondary glaucoma and cataract 
progression need to be investigated over a prolonged pe-
riod of follow-up. Cataract progression was not signifi-
cant in this short follow-up period and did not affect vi-
sual acuity outcome measurements, and might not have 
progressed as described in other studies  [7] due to the 
limited follow-up of our investigation. However, our trial 
is among the first to investigate the combination of an 
anti-VEGF treatment and the dexamethasone slow-re-
lease implant.
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